Q2 EPS Forecast for Revolution Medicines Raised by Analyst

Revolution Medicines, Inc. (NASDAQ:RVMD) – Stock analysts at Leerink Partnrs boosted their Q2 2025 EPS estimates for shares of Revolution Medicines in a report released on Sunday, June 29th. Leerink Partnrs analyst J. Chang now anticipates that the company will post earnings of ($1.06) per share for the quarter, up from their previous estimate of ($1.17). The consensus estimate for Revolution Medicines’ current full-year earnings is ($3.49) per share. Leerink Partnrs also issued estimates for Revolution Medicines’ Q3 2025 earnings at ($1.07) EPS, Q4 2025 earnings at ($1.08) EPS, FY2025 earnings at ($4.34) EPS and FY2026 earnings at ($4.60) EPS.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($1.13) EPS for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.01). During the same period in the previous year, the company posted ($0.70) EPS.

Several other analysts have also commented on the company. Wedbush reaffirmed an “outperform” rating and issued a $73.00 price target (up previously from $67.00) on shares of Revolution Medicines in a research note on Tuesday, June 24th. Oppenheimer lifted their price objective on Revolution Medicines from $70.00 to $75.00 and gave the company an “outperform” rating in a report on Thursday, May 8th. Needham & Company LLC restated a “buy” rating and issued a $57.00 target price on shares of Revolution Medicines in a research note on Tuesday, June 24th. HC Wainwright reiterated a “buy” rating and set a $72.00 target price (down previously from $73.00) on shares of Revolution Medicines in a research report on Wednesday, May 14th. Finally, Stifel Nicolaus cut their price target on shares of Revolution Medicines from $78.00 to $64.00 and set a “buy” rating for the company in a report on Tuesday, April 1st. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $67.58.

Revolution Medicines Trading Down 0.5%

RVMD stock opened at $37.00 on Wednesday. Revolution Medicines has a 1-year low of $29.17 and a 1-year high of $62.40. The business’s 50 day moving average is $39.58 and its 200-day moving average is $39.76. The firm has a market cap of $6.89 billion, a P/E ratio of -9.25 and a beta of 1.06.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. IFP Advisors Inc bought a new stake in Revolution Medicines during the 4th quarter worth about $34,000. Banque Transatlantique SA acquired a new stake in shares of Revolution Medicines during the 1st quarter worth approximately $42,000. Quarry LP acquired a new stake in Revolution Medicines during the 1st quarter worth $50,000. Twin Tree Management LP bought a new stake in shares of Revolution Medicines during the 1st quarter valued at $58,000. Finally, Sterling Capital Management LLC lifted its stake in shares of Revolution Medicines by 588.7% in the 4th quarter. Sterling Capital Management LLC now owns 1,956 shares of the company’s stock valued at $86,000 after purchasing an additional 1,672 shares during the period. Institutional investors own 94.34% of the company’s stock.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.